The above RNA-seq analysis showed that ICAM1-DXd treatment not only directly ablates CCA cells but also improves tumor immune microenvironment via significantly upregulating the type I interferon signaling pathway in a PDX model. The gene discussed is ICAM1; the disease is cholangiocarcinoma.